Brief: Neurotech International Says Neurotech Phase II/III Autism Trial Meets Primary Endpoint
17/04/2024 02:22
April 17 (Reuters) - Neurotech International Ltd
NTI.AX :
* NEUROTECH PHASE II/III AUTISM TRIAL MEETS PRIMARY ENDPOINT
Further company coverage: NTI.AX
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt